Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07115914 · ClinicalTrials.gov registry record · NA
PSMA PET for Surveillance After Focal Therapy
A NA study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer (Diagnosis), sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT07115914 is a NA study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer (Diagnosis) that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 62 participants, below the 126-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07115914, a NA study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer (Diagnosis), is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is about adding PSMA PET (Prostate Specific Membrane Antigen- Positron Emission Tomography) to routine magnetic resonance imaging (MRI) scans to help detect prostate cancer recurrence in men who have undergone focal therapy for prostate cancer. PSMA PET and multiparametric (mpMRI are both imaging tests that help detect prostate cancer in the body. A PSMA PET scan, or prostate-specific membrane antigen positron emission tomography scan, is an imaging test that scans and takes pictures of the prostate. PSMA scans use a specialized radioactive imaging dye that sticks to the proteins that are typically found in prostate cancer cells. This imaging dye helps locate areas of prostate cancer anywhere in the body, both inside and outside prostate. An mpMRI, or a multiparametric (mp) MRI scan, is also an imaging test that scans and takes detailed pictures of the prostate. Unlike regular MRIs, an mpMRI produces a more detailed image of the prostate. Similar to PET scans, mpMRI scans also use an imaging dye that helps the pictures of the prostate appear clearer on scans. This study will be funded by Blue Earth Diagnostics, a molecular imaging company based in England.
Conditions Studied
Interventions
- RADIATION PSMA PET/CT scan
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2028-08-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07115914
The ClinicalTrials.gov registry entry for NCT07115914 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (51% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which PSMA PET/CT scan is the first listed.
NCT07115914 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07115914 about?
NCT07115914 is a clinical study titled "PSMA PET for Surveillance After Focal Therapy". This study is about adding PSMA PET (Prostate Specific Membrane Antigen- Positron Emission Tomography) to routine magnetic resonance imaging (MRI) scans to help detect prostate cancer recurrence in men who have undergone focal therapy for prostate cancer. PSMA PET and multiparametric (mpMRI are both...
What is the current status of trial NCT07115914?
This trial is currently recruiting. It is a NA study. The enrollment target is 62 participants. The study started on 2025-11-19. Estimated completion is 2028-08-01.
What conditions does trial NCT07115914 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Cancer Metastatic Disease.
What interventions are being tested in trial NCT07115914?
The interventions under investigation include: PSMA PET/CT scan (RADIATION).
Who is sponsoring clinical trial NCT07115914?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07115914 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
RECRUITING · NA
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
RECRUITING
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.